Overview

Morphine to Maximize the Benefits of Exercise Training in COPD or ILD and Persistent Breathlessness

Status:
Unknown status
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the role of low-dose immediate-release oral morphine as a novel adjunct pharmacotherapy to enable symptomatic adults with advanced chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD) to exercise at higher intensities for longer durations and maximize the psycho-physiological benefits of a supervised exercise training program. We hypothesize that, compared to placebo, exercise training with oral morphine will result in relatively greater improvements in exercise endurance time and intensity ratings of perceived breathlessness during constant-load cardiopulmonary cycle exercise testing (CPET) at 75% of peak power output (PPO).
Phase:
Phase 2
Details
Lead Sponsor:
Dennis Jensen, Ph.D.
Treatments:
Morphine